Clinical trialPhase 3Terminated
Aflibercept Compared to Placebo in Term of Efficacy in Patients Treated With Gemcitabine for Metastatic Pancreatic Cancer
A Multinational, Randomized, Double-blind Study, Comparing the Efficacy of Aflibercept Once Every 2 Weeks Versus Placebo in Patients Treated With Gemcitabine for Metastatic Pancreatic Cancer
- Outcome
- Stopped earlyData Monitoring Committee concluded after a planned interim analysis that aflibercept added to gemcitabine would be unable to demonstrate improved survival (Other)
- Phase
- Phase 3
- Status
- Terminated
- Study type
- Interventional
- Start
- December 2007
- Expected end
- November 2010
- Enrollment
- 546 participants
- Sites
- 24
- Primary outcomes
- Overall Survival (OS)
- Sponsor
- Industry
- Results posted
- 2012-09-25
- Last update
- 7 June 2016
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.
Try
Papers 1
- Registry-listed results paperRandomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receivi… DOI 10.1016/j.ejca.2013.04.002↗
The registry lists these as results papers; in a hand check of 27 such links about 78% reported the trial’s results, so read the paper before treating it as the outcome.